Survival Rate of Liver Transplantation in Asia: A Systematic Review and Meta-Analysis

Mousa Ghelichi-Ghojogh 1, *Abdolhalim Rajabi 2, Fateme Mohammadizadeh 1, Layla Shojaie 3, Mouhebat Vali 1, Sima Afrashteh 1, Soheil Hassanipour 4, Hossein-Ali Nikbakht 5, Rozhan Khezri 6, Ehsan Allah Kalteh 7, *Mohammad Fararouei 8

1. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
2. Health Management and Social Development Research Center, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
3. Division of GI/Liver, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
4. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
5. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
6. Urmia Health Center, Urmia University of Medical Sciences, Urmia, Iran
7. Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, Iran
8. HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding Authors: Emails: fararooei@gmail.com; drrajabi.a@goums.ac.ir

(Rceived 16 Nov 2021; accepted 19 Jan 2022)

Abstract

Background: Liver transplantation is one of the most effective treatments for acute liver failure, chronic liver cirrhosis, and hepatocellular carcinoma. This study was implemented to evaluate the survival rate of liver transplant in Asia.

Methods: Studies that investigated the survival rate of liver transplant were selected using a systematic search strategy in the following databases: Medline, Embase, Scopus, ProQuest, ISI Web of Science, and Cochrane to Nov 30th, 2020. Pooled survival rate and 95% confidence intervals were calculated using Der-Simonian and Laird method. Stata 16.0 (Stata Corp, College Station, TX, USA) was used for analysis.

Results: One, 2, 3, 5, and 10-year survival rates of liver transplant were estimated to be 85%, 80%, 75%, 73%, and 71%, respectively. The results of the univariate meta-regression for defining the sources of heterogeneity for one-Year survival rate (SR) showed significant effects of bias (β high risk/ moderate risk =0.059, 95% CI: 0.002, 0.115, P-Value=0.04) and follow up time (β=0.0002, 95% CI: -0.0003, -0.00, P-Value=0.02) on heterogeneity.

Conclusion: The survival rate of liver transplant in Asia is comparable with the corresponding rate reported in the United States and Europe. This study provides a better view of the efficiency of medical cares, regarding liver transplantation. Medical care be enhanced to increase the survival of liver transplant patients.

Keywords: Liver transplantation; Survival analysis; Meta-analysis; Asia

Introduction

Liver Transplantation (LT) has been identified as one of the most effective treatments for acute liver failure, chronic liver cirrhosis, and hepatocellular carcinoma (1, 2). Since then, liver trans-
plantation has evolved rapidly, and the survival rate is being improved significantly over the past 25 years (lately 96% and 71% for 1-year and 10-year survival respectively) (3). In 2016, a global estimate suggested that the United States and China had the first and second largest number of liver transplantation with 7496 and 3264 cases, respectively (1). In addition, an increasing trend in LTs has been reported from different countries (4).

As a global average, the one, 10, and 18-year survival rates of liver transplantation are reported to be between 83%-88%, 68%-72%, and 48%-55%, respectively (5). In addition, the 5-year survival rates of liver transplantation for Asian, Spanish, white, and black patients were 74%, 65%, 68%, and 57% respectively (6). Moreover, in 2020 years LT in Europe achieved respectable 1- and 5-year overall survival rates of 86% and 74% (7, 8). In the United States, years one- and 5-year graft survivals for LDLT recipients were 88.4% and 78.1%, respectively, compared with 92.5% and 80.7% in propensity-score matched DBD recipients (P=0.005), respectively. Older donor age, recipient diabetes and life support requirement were significantly associated with graft failure among LDLT recipients (P<0.05)(9). Various factors such as age, sex, ethnicity, surgical techniques, type of immunosuppressive drugs, and even the individual's economic and social status affect the survival rate of liver-transplanted patients (10, 11).

Liver transplantation has revolutionized the acute prognosis of liver failure via increasing the survival of patients by 20% to 80% in 1-year and 70% in 5-year survival of the patients (3). Understanding the survival rate of liver transplants in Asia can provide valuable information on the effectiveness of the treatment strategies and determinants of the transplantation outcome. We found no comprehensive study on liver transplantation's survival rate in Asian countries. We aimed to do a systematic review and meta-analysis on the published studies to determine the survival rate and its general determinants of liver transplantation in Asia.

Methods

The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines were followed for the current study (12).

Search strategy

Studies that investigated the survival rate of patients with liver transplant were identified using a defined search strategy in the following databases: Medline, Embase, Scopus, ProQuest, ISI Web of Science, and Cochrane to November 30th, 2020. Moreover, we reviewed the reference lists from retrieved articles to search for further relevant studies.

Eligibility criteria

Each identified study was independently reviewed by two reviewers (FM and RKH) to determine whether the study was eligible for being included in the meta-analysis. The inclusion criteria were as follow: 1) prospective design; 2) all studies conducted on the SR of liver transplantation patients in Asia; 3) only articles published in English were included, and 4) animal studies, reviews, comments, and editorials were excluded. This study was approved by the research Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1400.257).

Data extraction and quality assessment

From each included study, the following data were extracted: first author, publication year of the study, where the study was performed, characteristics of the study population, follow up time, patients' average age, the study sample size, and the study results.

The quality of the included studies were defined by Hoy’s checklist (13). The studies were categorized as low, moderate, and high risk of bias if their scores were equal or more than 7, between 4 and 6, and less than 4 respectively.

Statistical analysis

For estimating the pooled survival rates, we used random-effects meta-analysis. Cochran Q test
was performed ($P<0.001$, CI 95%) to evaluate the heterogeneity among the studies and the presence of heterogeneity was analyzed using inconsistency test ($I^2>50\%$) (Higgins and Thompson 2002). Subgroup analysis was performed based on country and risk of bias. We did meta-regression analyses to identify factors that modify the survival rate of the patients and contribute to heterogeneity between the studies’ results (14). Publication bias was assessed by funnel plot and trim and fill analysis (15). The Stata 16.0 (Stata Corp, College Station, TX, USA) was used for analysis.

## Results

### Description of studies

The search identified 3046 studies. In total, 713 were duplicates, 2156 defined irrelevant after reading their titles and abstracts, and 60 articles were not original (i.e. letter, commentary, review) or did not meet the inclusion criteria. As such, 117 studies (16-127), recruiting 406,464 participants, were included in this meta-analysis (Fig. 1).

![Flow chart of the included eligible studies in systematic review](fig1)

All studies were cohort. Of 117 studies included in this meta-analysis, 113, 22, 75, 88, and 16 reported one-year, two-year, three-year, five-year, and ten-year survival rates, respectively. Of the included studies, 39 were from China, 30 from Japan, 14 from Iran and the remaining studies...
(n=34) were from other countries in the Asia continent.

**Assessment of the Risk of Bias**
The risk of bias of the included studies, 10 were in the high risk of bias category, 85 studies in moderate risk and 22 studies were in the low risk of bias.

**Survival rate**

| Study Duration (Years) | Survival Rate with 95% CI | Weight (%) |
|------------------------|---------------------------|------------|
| Pooled 1-YR (95% CI)   | 0.85 [0.84, 0.87]         | 20.86      |
| Pooled 2-YR (95% CI)   | 0.80 [0.75, 0.85]         | 19.17      |
| Pooled 3-YR (95% CI)   | 0.75 [0.72, 0.78]         | 19.89      |
| Pooled 5-YR (95% CI)   | 0.73 [0.70, 0.77]         | 19.89      |
| Pooled 10-YR (95% CI)  | 0.71 [0.68, 0.74]         | 20.19      |

Heterogeneity: $I^2 = 0.01$, $I^2 = 98.01\%$, $H^2 = 25.04$

Random-effects DerSimonian-Laird model

![Fig. 2: Pooled survival rate of liver transplantation](image1)

In this study one, 2, 3, 5, and 10-year survival rates (SR) of liver transplant were estimated to be 85%, 80%, 75%, 73%, and 71%, respectively (Fig. 2). Also, the result of test for group difference was not significant ($Q=\chi^2(2)=6.60$, $P$-Value=0.16 (Fig. 3). Survival rates of liver transplantation for different times according to countries and quality of studies are presented in Fig. 4.

![Fig. 3: One-years survival rate of liver transplantation](image2)
### A

| Study                  | K | Survival Rate with 95% CI |
|------------------------|---|--------------------------|
| **Risk of Bias**       |   |                          |
| Moderate Risk of Bias  | 20| 0.80 [ 0.76, 0.85]        |
| Low Risk of Bias       | 2 | 0.79 [ 0.53, 1.05]        |
| Test of group differences: $Q_0(1) = 0.00, p = 0.95$ |   |                          |
| **Country**            |   |                          |
| China                  | 10| 0.74 [ 0.64, 0.83]        |
| Hong Kong              | 1 | 0.80 [ 0.60, 1.00]        |
| India                  | 1 | 0.75 [ 0.59, 0.91]        |
| Iran                   | 6 | 0.86 [ 0.80, 0.91]        |
| Japan                  | 3 | 0.79 [ 0.65, 0.93]        |
| South Korea            | 1 | 0.92 [ 0.87, 0.98]        |
| Test of group differences: $Q_0(5) = 14.54, p = 0.01$ |   |                          |
| **Overall**            |   |                          |
| Heterogeneity: $I^2 = 0.01, I^2 = 90.82\%, H^2 = 10.89$ |   |                          |
| Test of $\theta = 0$: $Q(21) = 228.74, p = 0.00$ |   |                          |

Random-effects DerSimonian-Laird model

### B

| Study                  | K | Survival Rate with 95% CI |
|------------------------|---|--------------------------|
| **Risk of Bias**       |   |                          |
| Moderate Risk of Bias  | 69| 0.76 [ 0.72, 0.79]        |
| Low Risk of Bias       | 6 | 0.76 [ 0.67, 0.84]        |
| Test of group differences: $Q_0(1) = 0.00, p = 0.99$ |   |                          |
| **Country**            |   |                          |
| China                  | 29| 0.69 [ 0.64, 0.75]        |
| Hong Kong              | 1 | 0.73 [ 0.51, 0.96]        |
| India                  | 2 | 0.65 [ 0.38, 0.92]        |
| Iran                   | 8 | 0.80 [ 0.76, 0.84]        |
| Japan                  | 15| 0.79 [ 0.77, 0.82]        |
| Kazakhstan             | 1 | 0.80 [ 0.64, 0.96]        |
| Saudi Arabia           | 1 | 0.85 [ 0.80, 0.90]        |
| Singapore              | 3 | 0.74 [ 0.66, 0.83]        |
| South Korea            | 4 | 0.82 [ 0.56, 1.07]        |
| Taiwan                 | 10| 0.83 [ 0.78, 0.88]        |
| Thailand               | 1 | 0.76 [ 0.65, 0.86]        |
| Test of group differences: $Q_0(10) = 25.00, p = 0.01$ |   |                          |
| **Overall**            |   |                          |
| Heterogeneity: $I^2 = 0.02, I^2 = 99.48\%, H^2 = 190.61$ |   |                          |
| Test of $\theta = 0$: $Q(74) = 14105.12, p = 0.00$ |   |                          |

Random-effects DerSimonian-Laird model

---

Fig. 4: A: 2-years survival rate of liver transplantation, B: 3-years survival rate of liver transplantation

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
**Meta-regression analyses**

The results of the univariate meta-regression for defining the sources of heterogeneity for one-Year SR showed significant effects of bias ($\beta_{\text{high risk/moderate risk}} = 0.059$, P-Value = 0.04) and follow up time ($\beta = -0.0002$, P-Value = 0.02) on heterogeneity. The sources of heterogeneity for three-Year SR were time ($\beta_{2005-2010/\text{before 2005}} = -0.102$, P-Value = 0.03) and the length of follow up time ($\beta = -0.0014$, P-Value = 0.001). None of the covariates had a significant effect on heterogeneity of five-Year SR (Table 1).

### Table 1: Meta-regression results for one, three, and five-Year survival rates of liver transplant

| Variables                        | 1-YSR |     | 3-YSR |     | 5-YSR |     |
|----------------------------------|-------|-----|-------|-----|-------|-----|
|                                  | $\beta$ (95% CI) | P-value | $\beta$ (95% CI) | P-value | $\beta$ (95% CI) | P-value |
| Risk of bias                     |       |     |       |     |       |     |
| High risk of bias                | Ref   |     | Ref   |     | Ref   |     |
| Moderate Risk of Bias            | 0.059 (0.002, 0.115) | 0.04 | -     | -    | -0.044 (-0.200, 0.111) | 0.56 |
| Low risk of bias                 | 0.015 (-0.048, 0.079) | 0.63 | -0.013 (-0.14, 0.12) | 0.84 | -0.063 (-0.240, 0.114) | 0.48 |
| Date of publication              |       |     |       |     |       |     |
| Before 2005                      | Ref   |     | Ref   |     | Ref   |     |
| 2005-2010                        | 0.025 (-0.016, 0.066) | 0.23 | -0.102 (-0.19, -0.008) | 0.03 | -0.0073 (-0.126, 0.112) | 0.90 |
| After 2010                       | 0.015 (-0.024, 0.055) | 0.44 | -0.054 (-0.14, -0.034) | 0.23 | 0.0103 (-0.102, 0.123) | 0.85 |
| Follow up time                   | -0.0002 (-0.0003, 0.0) | 0.02 | 0.0014 (0.0006, 0.002) | 0.001 | 0.0003 (-0.00007, 0.0008) | 0.10 |
| Year of publication              | 0.0014 (-0.002, 0.004) | 0.40 | 0.0000 (-0.008, 0.008) | 0.99 | 0.0026 (-0.0071, 0.012) | 0.59 |
| Sample size                      | -1.24e-08 (-5.94e-07, 5.69e-07) | 0.96 | -2.37e-07 (-1.44e-06, 9.63e-07) | 0.69 | -1.78e-07 (-1.61e-06, 1.25e-06) | 0.80 |

**Publication bias**

When we plotted the one, three, and five-Year survival rate; there was no publication bias. Based on the Trim and fill method no study was identified to collaborate publication bias for any survival time.

**Discussion**

In this meta-analysis, the probability of progression from liver transplant to the transplant rejection in 1, 2, 3, 5, and 10 years was estimated to be 85%, 80%, 75%, 73%, and 71%, respectively. The liver transplantation survival rate in Asia is comparable with the corresponding rate reported from the USA and Europe.

Factors that can affect the survival of liver transplant include disease type, clinical features, and the age of the patients. In more details, the chance of survival of patients is strongly related to the type of disease. Patients with fulminant and chronic types of disease are considerably different with regard to the survival rate, as most deaths occur in the first six months after transplantation among patients with acute liver failure (128, 129). Age is another influential variable as the function of organs, such as the liver, reduces with age (1). However, there is no cut-point recommended for the age of recipients and donors for longer survival of liver transplantation.

In addition, it is essential to consider the cause of death following each transplant. The leading causes of death are secondary to recurrent prima-
ry liver disease, especially malignancy and cirrhosis due to hepatitis C virus (HCV) (130). Graft dysfunction, technical obstacles, and infection are among the other reasons for mortality following liver transplant (131). The highest risk of mortality associated with hepatic transplantation is during the first year postoperation, especially the first three months (132). Men and patients older than 60 year had poorer outcomes than women and younger cases (133). However, the cause of transplantation and the epidemiology of liver disease are increasingly evolving and becoming more weighted by HCV, causing a lower survival rate, compared to many other diseases. In other words, patients with HCV are distinct from the cases of primary biliary cirrhosis or primary sclerosing cholangitis (PSC), a phenomenon that makes this issue even more complex (7, 128). Although the comparable survival rates in the USA, Europe, and Asia are due to the similarity in health care practices and the expertise of surgeons, a much wider view is needed to reach a defined conclusion.

Comparing the results of studies based on their publication year, we found that the publication time of the articles was one of the factors influencing the heterogeneity of the results suggesting survival is being improved with the time goes by Smits et al. reported the same pattern in the survival of patients. The authors also reported the age of donor and recipient and blood type compatibility as significant predictors of the transplant’s survival (4, 134). According to the studies published in recent years, the transplant survival rates of European and American patients are catching up, and as observed in our study, the survival rate in Asia is becoming comparable. The improving patients’ survival rate seems to continue over time if transplantations at various times are conducted among patients with more desirable clinical conditions (9, 128). Therefore, factors related to the donor, recipient, perioperative, and postoperative phases of transplantation may influence the survival rate of the grafts (135). For example, the donor’s characteristics that may result in poorer outcomes include older age, high body mass index, length of hospitalization, usage of vasopressors, and the presence of infection. Perioperative factors encompass cold and warm ischemia time, blood product requirements, and surgical difficulties are other factors that affect the survival of the graft (135, 136). Finally, postoperative factors are primary non-function, renal dysfunction, center experience, need for mechanical ventilation, and prolonged stay in an intensive care unit.

**Strengths and Limitations**

The risk of bias and the period of the study did significantly affect the survival rate of the patients. Moreover, we assessed follow-up time, year of publication, and sample size. We had few limitations in our meta-analysis. The studies on the subject did not report the characteristics of donors and recipients and the type of the selected surgical procedures, factors that can be effective in the survival of transplant. We observed statistical heterogeneity in our study.

**Conclusion**

Our results presented the survival rate of liver transplantation in Asia and revealed that the survival rate is comparable to that in the US and European countries. In addition, the 1 and 5-year survival rates reported in the Eastern Mediterranean countries were similar to the United States.

We need further studies to define the determinants of survival of liver transplant patients. We need to consider these factors when comparing the survival of the patients. Further studies considering these factors in different subgroups are needed for estimating the survival of the grafts in different geographical locations. Medical care be enhanced to increase the survival of liver transplant patients.

**Journalism Ethics considerations**

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission,
Acknowledgements

This study was supported financially by Shiraz University of Medical Sciences, Shiraz, Iran (Grant Number: 22745). Additional information is available from the corresponding author and can contact the corresponding author.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Madreseh E, Mahmoudi M, Nassiri-Toosi M, et al (2020). Post Liver Transplantation Survival and Related Prognostic Factors among Adult Recipients in Tehran Liver Transplant Center; 2002–2019. Arch Iran Med, 23(5):326-34.

2. Ghelichi-Ghojogh M, Javanian M, Amiri S, et al (2022). The survival rate of liver transplantation in children: a systematic review and meta-analysis. Pediatr Surg Int, 38(9):1177-1186.

3. Burra P, Burroughs A, Graziadei I, et al (2016). EASL clinical practice guidelines: liver transplantation. J Hepatol, 64(2):433-85.

4. Wahid NA, Rosenblatt R, Brown Jr RS (2021). A review of the current state of liver transplantation disparities. Liver Transpl, 27(3):434-43.

5. Yang LS, Shan LL, Saxena A, et al (2014). Liver transplantation: a systematic review of long-term quality of life. Liver Int, 34(9):1298-313.

6. Kemmer NM, Neff GWJT (2009). Liver transplantation trends and survival in the Asian population. Transplantation, 88(3):392-4.

7. Müller PC, Kabacam G, Vibert E, et al (2020). Current status of liver transplantation in Europe. Int J Surg, 82S:22-9.

8. Germani G, Zeni N, Zanetto A, et al (2020). Influence of donor and recipient gender on liver transplantation outcomes in Europe. Liver Int, 40(8):1961-71.

9. Cotter TG, Minhem M, Wang J, et al (2021). Living-Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes and Factors Associated with Outcomes. Liver Transpl, 27(7):1019-1031.

10. Åberg F, Gissler M, Karlsen TH, et al (2015). Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology, 61(2):668-77.

11. Kaido T (2020). Recent evolution of living donor liver transplantation at Kyoto University: How to achieve a one-year overall survival rate of 99%? Hepatobiliary Pancreat Dis Int, 19(4):328-33.

12. Moher D, Liberati A, Tetzlaff J, Altman DG (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg, 8(5):336-41.

13. Hoy D, Brooks P, Woolf A, et al (2012). Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol, 65(9):934-9.

14. Thompson SG, Higgins JP]Sim (2002). How should meta-regression analyses be undertaken and interpreted? Stat Med, 21(11):1559-73.

15. Mavridis D, Salanti G (2014). How to assess publication bias: funnel plot, trim-and-fill method and selection models. Evid Based Ment Health, 17(1):30.

16. Hirata M, Sugawara Y, Makuuchi M (2002). Living-donor liver transplantation at Tokyo University. Clin Transpl, 215:215-9.

17. Ikekami T, Kawasaki S (2002). Liver transplantation for fulminant hepatitis. Nihon Geka Gakkai Zasshi, 103(5):401-7.

18. Wei W, Tsoi N, Ng I, et al (2002). Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J, 8(4):240-4.

19. Zheng S-S, Liang T-B, Wang W-L, et al (2002). Clinical experience in liver transplantation from an organ transplantation center in China. Hepatobiliary Pancreat Dis Int, 1(4):487-91.

20. Sugawara Y, Makuuchi M, Kaneko J, et al (2003). Living-donor liver transplantation in adults:

Available at:  http://ijph.tums.ac.ir
Tokyo University experience. J Hepatobiliary Pancreat Surg, 10(1):1-4.

21. Wong A, Lo C, Liu C (2003). Outcome for Hong Kong residents undergoing cadaveric liver transplantation in mainland China. Hong Kong Med J, 9(3):165-70.

22. Hashikura Y, Kawasaki S (2004). Living donor liver transplantation: issues regarding left liver grafts. HPB (Oxford), 6(2):99-105.

23. Hasegawa K, Sugawara Y, Imamura H, et al (2005). Living donor liver transplantation for primary biliary cirrhosis: retrospective analysis of 50 patients in a single center. Transpl Int, 18(7):794-9.

24. Malek-Hosseini S, Mehdizadeh A, Salahi H, et al (2005). Results of liver transplantation: analysis of 140 cases at a single center. Transplant Proc, 37(7):3157-8.

25. Yong C-C, Chen Y-S, Wang et al (2005). Deceased-donor liver transplantation: 10 years' experience at Chang Gung Memorial Hospital-Kaohsiung Medical Center. Chang Gung Med J, 28(3):133-41.

26. Zhou J, Fan J, Wu Z-q, et al (2005). Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China. Chin Med J (Engl), 118(08):654-9.

27. Bharat A, Brown DB, Crippin JS, et al (2006). Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg, 203(4):411-20.

28. Fan J, Zhou J, Xu Y, et al (2006). Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria. Zhonghua Yi Yi Xue Za Zhi, 86(18):1227-31.

29. Wai C, Lee Y, Selamat D, et al (2006). Liver transplantation in Singapore. Singapore Med J, 47(7):580-3.

30. Wang X-h, Yan L-n, Zhang F, et al (2006). Early experiences on living donor liver transplantation in China: multicenter report. Chin Med J (Engl), 119(12):1003-9.

31. Yokoi H, Isaji S, Yamagiwa K, et al (2006). The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg, 13(2):123-30.

32. Huang J (2007). Ethical and legislative perspectives on liver transplantation in the People's Republic of China. Liver Transpl, 13(2):193-6.

33. Morioka D, Egawa H, Kasahara M, et al (2007). Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. Am Surg, 245(2):315-25.

34. Rakela J, Fung JJ (2007). Liver transplantation in China. Liver Transpl, 13(2):182.

35. Concejero A, Chen C-L, Wang C-C, et al (2008). Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation, 85(3):398-406.

36. Eguchi S, Takatsuki M, Hidaka M, et al (2008). Evolution of living donor liver transplantation over 10 years: experience of a single center. Surg Today, 38(9):795-800.

37. Ikekami T, Taketomi A, Soejima Y, et al (2008). Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg, 206(3):412-8.

38. Lin N-C, Hsia C-Y, Loong C-C, et al (2008). Liver transplantation at a small-volume procedure center—preliminary results from Taipei Veterans General Hospital. J Chin Med Assoc, 71(4):186-90.

39. Pandey D, Wai CT, Lee KH, Tan KC (2008). Living donor liver transplantation for hepatocellular carcinoma: a single centre experience. Indian J Gastroenterol, 27:148-52.

40. Shen Z-y, Wang Z-f, Zhu Z-j, et al (2008). Pediatric liver transplantation in 31 consecutive children. Chin Med J (Engl), 121(20):2001-3.

41. Chan KL, Fan ST, Lo CM, et al (2009). Pediatric liver transplantation in Hong Kong: a domain with scarce deceased donors. J Pediatr Surg, 44(12):2316-21.

42. Chen GH (2009). Liver transplantation in China: retrospect and prospect. Chin Med J (Engl), 122(19):2229-30.

43. Cheng F, Li GQ, Zhang F, et al (2009). Outcomes of living-related liver transplantation for Wilson's disease: a single-center experience in China. Transplantation, 87(5):751-7.

44. García-Valdecasas JC, Fuster J, Fondevila C, Calatayud D (2009). Adult living-donor liver transplantation. Gastroenterol Hepatol, 32(8):577-83.
45. Fan ST, Wang H, Lam BK (2009). Follow-up of Chinese liver transplant recipients in Hong Kong. *Liver Transpl*, 15(5):544-50.
46. Kuo WT, Hsia CY, Loong CC, et al (2009). Outcome of foreign residents undergoing deceased donor liver transplantation in China: a single-center experience in Taiwan. *Liver Transpl*, 15(11):1579-85.
47. Li J, Yan LN, Yang J, et al (2009). Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. *World J Gastroenterol*, 15(33):4170-6.
48. Sabet B, Rajaeefard A, Nikeghbalian S, Malek-Hosseini SA (2009). Six years liver transplants outcome in Shiraz transplant center. *J Isfahan Med School*, 27(99):543-50.
49. Xiao L, Fu ZR, Ding GS, et al (2009). Liver transplantation for hepatitis B virus-related hepatocellular carcinoma: one center's experience in China. *Transplant Proc*, 41(5):1717-21.
50. Xiao L, Fu ZR, Ding GS, et al (2009). Prediction of survival after liver transplantation for chronic severe hepatitis B based on preoperative prognostic scores: a single center's experience in China. *World J Surg*, 33(11):2420-6.
51. Yoshitoshi EY, Takada Y, Oike F, et al (2009). Long-term outcomes for 32 cases of Wilson's disease after living-donor liver transplantation. *Transplantation*, 87(2):261-7.
52. Allam N, Al Saghier M, El Sheikh Y, et al (2010). Clinical outcomes for Saudi and Egyptian patients receiving deceased donor liver transplantation in China. *Ann J Transplant*, 10(8):1834-41.
53. Chen CL, Concejero AM (2010). Liver transplantation for hepatocellular carcinoma in the world: the Taiwan experience. *J Hepatobiliary Pancreat Sci*, 17(5):555-8.
54. Mohamed El Moghazy W, Ogura Y, Mutsuko M, et al (2010). Pediatric living-donor liver transplantation for acute liver failure: analysis of 57 cases. *Transpl Int*, 23(8):823-30.
55. Faraj W, Deborah Mukherji D, Falik H, et al (2010). Liver transplantation in Lebanon: A hard lesson to learn. *Ann Transplant*, 15(3):25-9.
56. Ikegami T, Soejima Y, Shirabe K, et al (2010). Evolving strategies to prevent biliary strictures after living donor liver transplantation. *Transplant Proc*, 42(9):3624-9.
57. Zhu M, Li Y, Xia Q, et al (2010). Strong impact of acute kidney injury on survival after liver transplantation. *Transplant Proc*, 42(9):3634-8.
58. Gwon DI, Sung KB, Ko Gy, et al (2011). Dual catheter placement technique for treatment of biliary anastomotic strictures after liver transplantation. *Liver Transpl*, 17(2):159-66.
59. Hu X-X, Yan L-N (2011). Retrospective analysis of prognostic factors after liver transplantation for intrahepatic cholangiocarcinoma in China: a single-center experience. *Hepatogastroenterology*, 58(109):1255-9.
60. Hu Z, Zhou J, Xu X, et al (2012). Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. *PLoS One*, 7(5):e36587.
61. Kim J, Kwon C, Joh J-W, et al (2012). Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria. *Transplant Proc*, 44(2):403-8.
62. Lee H-J, Hwang S, Ahn C-S, et al (2012). Long-term outcomes of portal Y-graft interposition for anomalous right portal veins in living donor liver transplantation. *Transplant Proc*, 44(2):454-6.
63. Mizuta K, Urahashi T, Ihara Y, et al (2012). Living donor liver transplantation in children with cholestatic liver disease: a single-center experience. *Transplant Proc*, 44(2):469-72.
64. Oh S, Kim K, Kim D, et al (2012). Clinical experience of more than 200 cases of pediatric liver transplantation at a single center: improved patient survival. *Transplant Proc*, 44(2):484-6.
65. Poon K-S, Chen T-H, Jeng L-B, et al (2012). A high model for end-stage liver disease score should not be considered a contraindication to living donor liver transplantation. *Transplant Proc*, 44(2):316-9.
66. Wai C-T, Woon W-A, Tan Y-M, et al (2012). Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation. *Transplant Proc*, 44(2):516-9.

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
67. Wai C-T, Woon W-A, Tan Y-M, et al (2012). Pretransplant Model for End-stage Liver Disease score has no impact on posttransplant survival in living donor liver transplantation. *Transplant Proc*, 44(2):396-8.

68. Xu I, Xu M-Q, Yan L-N, et al (2012). Causes of mortality after liver transplantation: a single center experience in mainland china. *Hepatogastroenterology*, 59(114):481-4.

69. Yoshizumi T, Shirabe K, Ikekami T, et al (2012). Impact of human T cell leukemia virus type 1 in living donor liver transplantation. *Am J Transplant*, 12(6):1479-85.

70. Yu C-Y, Ou H-Y, Huang T-L, et al (2012). Hepatocellular carcinoma downstaging in liver transplantation. *Transplant Proc*, 44(2):412-4.

71. Haseli N, Hassanzade J, Dehghani SM, et al (2013). Living related donor liver transplantation in Iranian children: a 12-year experience. *Gastroenterol Hepatol Bed Bench*, 6(4):183-9.

72. Haseli N, Hassanzadeh J, Dehghani SM, et al (2013). Long-term survival and its related factors in pediatric liver transplant recipients of shiraz transplant center, shiraz, iran in 2012. *Hepat Mon*, 13(7):e10257.

73. Hu Z, Zhou J, Wang H, et al (2013). Survival in liver transplant recipients with hepatitis B or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. *PLoS One*, 8(4):e61620.

74. Jiang I, Yan L-N, Wen T-F, et al (2013). Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria. *Hepatobiliary Pancreat Dis Int*, 12(5):494-9.

75. Kasahara M, Umeshita K, Inomata Y, et al (2013). Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. *Am J Transplant*, 13(7):1830-9.

76. Kim JM, Kim KM, Yi N-J, et al (2013). Pediatric liver transplantation outcomes in Korea. *J Korean Med Sci*, 28(1):42-7.

77. Pillai VG, Chen C-L. (2016). Living donor liver transplantation in Taiwan—challenges beyond surgery. *Hepatobiliary Surg Nutr*, 5(2):145-50.

78. Lei J, Yan L (2013). Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies. *J Gastrointest Surg*, 17(6):1116-22.

79. Lei J-Y, Wang W-T, Yan L-N (2013). Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. *World J Gastroenterol*, 19(36):6077-83.

80. Li C-T, Luo J, Zhang Z-W (2013). Risk factors for massive ascites after living donor liver transplantation in adult and impact of massive ascites on patient survival. *Sichuan Da Xue Xue Ban Yi Xue Ban*, 44(4):632-6.

81. Sun L-Y, Yang Y-S, Zhu Z-J, et al (2013). Outcomes in children with biliary atresia following liver transplantation. *Hepatobiliary Pancreat Dis Int*, 12(2):143-8.

82. Takada Y, Uemoto S (2013). Living donor liver transplantation for hepatitis C. *Sing Today*, 43(7):709-14.

83. Yoshizumi T, Ikekami T, Yoshiya S, et al (2013). Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. *Hepatol Res*, 43(7):709-16.

84. Al Sebayel MI, Abaalkhail FA, Al Bahili H, et al (2014). Liver transplantation at KFSHRC: Achievement and challenges. *Ann Saudi Med*, 34(2):103-6.

85. Kabling CS, Chen C-L, Concejero A, et al (2014). Section 18. Professional framework for liver transplantation for overseas patients: traveling for living donor liver transplantation. *Transplantation*, 97 Suppl 8:S75-9.

86. Kumaran V (2014). Role of liver transplantation for hepatocellular carcinoma. *J Clin Exp Hepatol*, 4(Suppl 3):S97-S103.

87. Lei JY, Wang WT, Yan LN (2014). Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. *Eur J Gastroenterol Hepatol*, 26(2):200-4.

88. Liang B-y, Huang Z-y, Zhou S-j, et al (2014). Primary results of salvage liver transplantation in the patients with unresectable recurrent hepatocellular carcinoma after initial liver resection. *Hepatogastroenterology*, 61(135):2014-20.

89. Wang P, Wang C, Li H, et al (2015). Impact of age on the prognosis after liver
transplantation for patients with hepatocellular carcinoma: a single-center experience. Onco Targets Ther, 8:3775-81.
90. Oh SH, Kim KM, Kim DY, et al (2014). Improved outcomes in liver transplantation in children with acute liver failure. J Pediatr Gastroenterol Nutr, 58(1):68-73.
91. Yabuta M, Shibata T, Shibata T, et al (2014). Long-term outcome of percutaneous transhepatic balloon angioplasty for portal vein stenosis after pediatric living donor liver transplantation: a single institute’s experience. J Vasc Interv Radiol, 25(9):1406-12.
92. Al Sebayel M, Abaalkhail F, Hashim A, et al (2015). Living donor liver transplant versus cadaveric liver transplant survival in relation to model for end-stage liver disease score. Transplant Proc, 47(4):1211-3.
93. Faraj W, Haydar A, Nounou GE, et al (2015). Update on liver transplants in Lebanon. Png Transplant, 25(3):271-5.
94. Sakamoto S, Kasahara M, Ogura Y, et al (2015). Current status of deceased donor split liver transplantation in Japan. J Hepatobiliary Pancreat Sci, 22(12):837-45.
95. Dong J, Zhu Y, Ma F, et al (2016). Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: a two-center experience. Medicine (Baltimore), 95(31):e4383.
96. Eguchi S, Furukawa H, Uemoto S, et al (2016). Outcomes of living donor liver transplantation alone for patients on maintenance renal replacement therapy in Japan: results of a Nationwide Survey. Transplant Direct, 2(6):e74.
97. Sugawara Y, Yamamoto H, Hibi T (2018). Living donor liver transplantation for patients with hepatocellular carcinoma in Japan. Hepatobiliary Pancreat Dis Int, 17(1):8-15.
98. Liu X, Wang B, Zhang X, et al (2016). Liver transplantation using donation after brain and cardiac death: a single-center experience in China. Transplant Proc, 48(6):1879-86.
99. Togashi J, Akamastu N, Kokudo N (2016). Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. Hepatobiliary Surg Nutr, 5(5):399-407.
100. Hosseini SAM, Nikeghbalian S, Salahi H, et al (2017). Evolution of liver transplantation program in Shiraz, Iran. Hepat Mon, 17(11):e60745.
101. Umesita K, Eguchi S, Egawa H, et al (2019). Liver transplantation in Japan: registry by the Japanese liver transplantation society. Hepatol Res, 49(9):964-80.
102. Ushigome H, Nakao T, Harada S, et al (2016). Elderly living donor liver transplant recipients over 60 Years old at a Japanese single center. Transplant Proc, 48(4):1115-8.
103. Wang T-J, Lin C-H, Chang S-N, et al (2016). Long-term outcome of liver transplant recipients after the development of renal failure requiring dialysis: a study using the National Health Insurance Database in Taiwan. Transplant Proc, 48(4):1194-7.
104. Yoshizumi T, Takada Y, Shirabe K, et al (2016). Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multicenter study in Japan. J Hepatobiliary Pancreat Sci, 23(6):333-41.
105. Zhang Q, Deng Y-L, Liu C, et al (2016). Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol, 22(43):9571-85.
106. Kositamongkol P, Sanphasitvong V, Sirivatanauksorn Y, et al (2017). Outcome of liver transplantation in hepatocellular carcinoma patients at Siriraj Hospital. Transplant Proc, 49(5):1114-1117.
107. Wei Q, Nemdharry RS, Zhuang R-Z, et al (2017). A good prognostic predictor for liver transplantation recipients with benign end-stage liver cirrhosis. Hepatobiliary Pancreat Dis Int, 16(2):164-8.
108. Wei L, Chen D, Zhang B, et al (2018). Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population. J Viral Hepat, 25(12):1576-81.
109. Hsu C-T, Chang M-H, Ho M-C, et al (2019). Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan. J Formos Med Assoc, 118(11):1537-45.
110. Zakaria HM, Salam AN, Ayoub II, et al (2017). Predictors of outcome of living donor liver transplantation for hepatocellular carcinoma. Indian J Surg, 79(4):299-307.

Available at: http://ijph.tums.ac.ir
111. Morise Z (2019). Developments and perspectives of laparoscopic liver resection in the treatment of hepatocellular carcinoma. *Surg Today*, 49(8):649-55.

112. Miura K, Sakamoto S, Shimata K, et al (2017). The outcomes of pediatric liver retransplantation from a living donor: a 17-year single-center experience. *Surg Today*, 47(11):1405-14.

113. Zongyi Y, Baifeng L, Funian Z, et al (2017). Risk factors of acute kidney injury after orthotopic liver transplantation in China. *Sá Rep*, 7:41555.

114. Kamo N, Kaido T, Yagi S, et al (2018). Liver transplantation for intermediate-stage hepatocellular carcinoma. *Liver Cancer*, 7(2):179-89.

115. Kasahara M, Umeshita K, Sakamoto S, et al (2018). Living donor liver transplantation for biliary atresia: an analysis of 2085 cases in the registry of the Japanese Liver Transplantation Society. *Am J Transplant*, 18(3):659-68.

116. Lee EC, Kim SH, Shim JR, Park SJ (2018). Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria. *Liver Transpl*, 24(1):35-43.

117. Lei M, Yan L-N, Yang J-Y, et al (2018). Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China. *World J Gastroenterol*, 24(48):5525-5536.

118. Malek-Hosseini SA, Jafarian A, Nikeghbalian S, et al (2018). Liver transplantation status in Iran: a multi-center report on the main transplant indicators and survival rates. *Arch Iran Med*, 21(7):275-82.

119. Zhong C-P, Xi Z-F, Xia Q (2018). Clinical analysis of liver transplantation in autoimmune liver diseases. *Hepatobiliary Pancreat Dis Int*, 17(1):27-31.

120. Chen W, Yadav DK, Bai X, et al (2019). Liver transplantation from voluntary organ donor system in China: a comparison between DBD and DCD liver transplants. *Gastroenterol Res Pract*, 2019:5736702.

121. Baimakhanov Z, Kaniev S, Doskhanov M, et al (2019). Evolution of Liver Transplantation in Kazakhstan: Two-Era Experience of a Single Center, the First Report. *Transplant Proc*, 51(10):3360-3363.

122. Shen Z, Gu C, Zheng H, et al (2019). A twenty-year review of clinical liver transplantation. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*, 31(3):269-80.

123. Kurata N, Ogura Y, Ogiso S, et al (2019). Splenectomy in living donor liver transplantation and risk factors of portal vein thrombosis. *Hepatobiliary Pancreat Dis Int*, 18(4):337-42.

124. Madreseh E, Mahmoudi M, Nassiri-Toosi M, et al (2020). Post Liver Transplantation Survival and Related Prognostic Factors among Adult Recipients in Tehran Liver Transplant Center; 2002–2019. *Arch Iran Med*, 23(5):326-334.

125. Basiraninia M, Dehghani SM, Razmjoee F, Derakhshan D (2020). Prevalence of Renal Dysfunction Among Pediatric Liver Transplant Recipients. *Iran J Kidney Dis*, 14(2):119-125.

126. Malek-Hosseini SA, Habibzadeh F, Nikeghbalian S (2019). Shiraz organ transplant center: the largest liver transplant center in the world. *Transplantation*, 103(8):1523-5.

127. Nikeghbalian S, Malekhosseini SA, Kazemi K, et al (2021). The largest single center report on pediatric liver transplantation: experiences and lessons learned. *Ann Surg*, 273(2):e70-e72.

128. Roberts MS, Angus DC, Bryce CL, et al (2004). Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. *Liver Transpl*, 10(7):886-97.

129. Dueandel S, Syversveen T, Solheim JM, et al (2020). Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. *Ann Surg*, 271(2):212-8.

130. Vogt DP, Henderson JM, Carey WD, Barnes DJS (2002). The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. *Surgery*, 132(4):775-80.

131. Cuervas-Mons V, Martinez AJ, Dekker A, et al (1986). Adult liver transplantation: an analysis of the early causes of death in 40 consecutive cases. *Hepatology*, 6(3):495-501.

132. Mora NP, Klintmalm GB, Solomon H, et al (1992). Survival after liver transplantation in 300 consecutive patients: the influence of age, clinical status, and pretransplant disease. *Transplant Proc*, 24(1):156-7.
133. Jain A, Reyes J, Kashyap R, et al (2000). Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. *Ann Surg*, 232(4):490-500.
134. Smits J, De Meester J, Persijn G, et al (1996). Long-term results of solid organ transplantation. Report from the Eurotransplant International Foundation. *Clin Transpl*, 109-27.
135. Saidi RF (2012). Current status of liver transplantation. *Arch Iran Med*, 15(12):772-6.
136. Kadohisa M, Inomata Y, Uto K, et al (2021). Impact of Donor Age on the Outcome of Living-donor Liver Transplantation: Special Consideration to the Feasibility of Using Elderly Donors. *Transplantation*, 105(2):328-37.